SunBio,Inc. (067370) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of SunBio,Inc. KRW 4,928, price KRW 5,640, upside -12.6%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SunBio,Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 4,945 KRW – 37,733 KRW · fair‑value band 1,887 KRW – 6,315 KRW · the 5,640 KRW price screens above the 4,928 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow SunBio in your weekly email
Every Wednesday you see whether SunBio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage.
Show more
SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage. The company offers MucoPEG, a medical device for treatment of dry mouth syndrome; and SynoGEL, a viscosupplement for arthritic Knee. Its preclinical stage biopharmaceuticals candidates target brain stroke and chronic anemia. It also manufactures and sells PEG derivatives. The company was founded in 1997 and is headquartered in Gunpo-si, South Korea.
Stock analysis
SunBio,Inc. (067370) currently trades at 5,640 KRW, while our model-based Fair Value estimate is 4,928 KRW, implying the stock looks roughly 14.4% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 10,669 KRW per share, and 9 of the 24 models we run sit above the 5,640 KRW price.
Bear case: the Asset-Based group reads lowest at 1,590 KRW, and 15 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 1,887 KRW (bear) to 6,315 KRW (bull), the price of 5,640 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
SunBio,Inc. reported revenue of 13.7B KRW in FY2025 versus 7.4B KRW in FY2022, a compound +22.6%/yr. Reported net income was 2.8B KRW in FY2025, compounding +47.6%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap 74.2B KRW (≈ $54.5M) · P/S ratio 34.2 · Dividend yield 1.2% · Net margin 20.4% · Return on equity 35.4% · Return on assets (EBIT) 4.7% · Operating margin 16.1% · Free cash flow 577M KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −13%, 067370 screens richer than that median.
Fair Value models
Bear 1,887 KRWFair Value 4,928 KRWBull 6,315 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+57.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.6%
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+2.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.1%
Dividend (yield on the price)1.2%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 37%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+59.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +56.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 10/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score58 · Top 25%
Fair Value upside−13% · Above median
Profitability
Return on equity (TTM)35% · Top 25%
Return on assets5% · Top 25%
Net margin (TTM)64% · Top 25%
Operating margin (TTM)16% · Top 25%
Growth and dividend
Revenue growth0% · Above median
Dividend yield (TTM)1.2% · Above median
Balance sheet
Debt / equity0.35× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SunBio,Inc. Fair Value". https://www.fairvalue-calculator.com/stock/067370
Frequently asked questions
Is SunBio,Inc. (067370) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4,928 KRW versus a price of 5,640 KRW, about −13% upside (overvalued).
What is the fair value of 067370?
Our model-based fair value for SunBio,Inc. is 4,928 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 5,640 KRW.
What is the quality score of 067370?
SunBio,Inc. has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SunBio,Inc. (067370)?
Our model-based price target is the fair value of 4,928 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 1,887 KRW, optimistic scenario 6,315 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the SunBio,Inc. stock forecast for 2026?
Our models put fair value at 4,928 KRW, about −13% upside versus a price of 5,640 KRW (overvalued). Cautious scenario 1,887 KRW, optimistic scenario 6,315 KRW. The calculation is refreshed regularly with new filings.
Does SunBio,Inc. pay a dividend?
SunBio,Inc. currently shows a dividend yield of about 1.24% relative to its recent price (as of Sep 24, 2026).
What growth is priced into SunBio,Inc. (067370)?
For today's price to be fair in a discounted-cash-flow model, SunBio,Inc. would have to grow free cash flow by +59.4 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +22.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 067370 use?
Our models discount SunBio,Inc. at 12.0 %: a base by market capitalisation (micro), damped by beta 0.65, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SunBio,Inc. that is +59.4 % per year a year over ten years, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has SunBio,Inc. (067370) delivered so far?
Over the past 3 years revenue at SunBio,Inc. grew +22.6 % a year. The price currently implies +59.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SunBio,Inc. (067370) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into SunBio,Inc. (+59.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SunBio,Inc. (067370)?
The free-cash-flow yield on the price is 0.84 %: that much free cash flow SunBio,Inc. produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SunBio,Inc. (067370)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SunBio,Inc. it is 4,928 KRW per share (as of Sep 24, 2026), against a price of 5,640 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is SunBio,Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 067370 trades above its calculated fair value: price 5,640 KRW, fair value 4,928 KRW, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 067370?
No. The price is what the market pays today (5,640 KRW); the fair value is what the company's own numbers justify (4,928 KRW). For SunBio,Inc. the two are 711.78 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is SunBio,Inc. worth?
The market values SunBio,Inc. at about 74.2B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 5,640 KRW; our models calculate a fair value of 4,928 KRW per share.
What do the bullish and bearish scenarios say about 067370?
Our models span a range for SunBio,Inc.: cautious scenario 1,887 KRW, base 4,928 KRW, optimistic 6,315 KRW per share (as of Sep 24, 2026, price 5,640 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SunBio,Inc. (067370)?
Balance-sheet figures for SunBio,Inc. (as of Sep 24, 2026): return on equity 35.4%, debt of 0.35 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 067370 from its 52-week high?
SunBio,Inc. trades at 5,640 KRW, about 32% below its 52-week high of 8,290 KRW and 14% above the low of 4,945 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 4,928 KRW is for.
Which stocks are comparable to SunBio,Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SunBio,Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price 5,640 KRW, calculated fair value 4,928 KRW (−13%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 067370 calculated?
We run SunBio,Inc. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,928 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. SunBio,Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SunBio,Inc. (067370)?
The closing price on Sep 23, 2026 was 5,640 KRW. Our model-based fair value is 4,928 KRW, about −13% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SunBio,Inc. right now?
The model range is unusually wide (1,887 KRW to 6,315 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of SunBio,Inc.
How large is the market capitalisation of SunBio,Inc. (067370)?
The market capitalisation of SunBio,Inc. is 74.2B KRW (≈ $54.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SunBio,Inc. (067370)?
The price-to-sales ratio of SunBio,Inc. is 34.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of SunBio,Inc. (067370)?
The dividend yield of SunBio,Inc. is 1.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SunBio,Inc. (067370)?
The net margin of SunBio,Inc. is 20.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SunBio,Inc. (067370)?
The return on equity (ROE) of SunBio,Inc. is 35.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SunBio,Inc. (067370)?
On an EBIT basis the return on assets of SunBio,Inc. is 4.7% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SunBio,Inc. (067370)?
The operating margin of SunBio,Inc. is 16.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much net debt does SunBio,Inc. (067370) carry?
The net debt of SunBio,Inc. is 25.7B KRW (fiscal year 2025, ≈ 44.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SunBio,Inc. in the live analysis
One click puts SunBio,Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
